Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”) Apr 26, 2019
Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates Apr 8, 2019
Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting Apr 2, 2019
Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update Feb 28, 2019
